Business
Hemostemix Announces Letter of Commitment, Non-Dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre Foundation
Calgary, Alberta--(Newsfile Corp. - January 19, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces Letter of Commitment, Non-Dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre FoundationCalgary, Alberta--(Newsfile Corp. - January 19, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (\"Hemostemix\" or the \"Company\") is pleased to announce it has received a $250,000 Letter of Commitment for funding from the McGill University Health Centre (MUHC) Foundation. The Letter of Commitment confirms that the MUHC Foundation will fund $250,000 of the clinical trial expenses and partner with Hemostemix, Dr. Nadia Giannetti and Dr. Renzo Cecere to complete a phase II double blind randomized clinical trial of ACP-01 as a treatment of ischemic cardiomyopathy at the McGill University Health Centre (MUHC).In 2020, the MUHC Foundation launched its $200 million Dream Big Campaign to change the course of lives and medicine. The Dream Big Campaign is designed to ensure bold innovations like ACP-01 are well supported by philanthropy. To reach that goal, Hemostemix and the MUHC Foundation are committed to working together with federal and provincial partners alongside donors to fund the phase II clinical trial at the McGill University Health Centre. \"Given our three investigator led studies of 179 ischemic cardiomyopathy subjects demonstrates ACP-01 is safe and generates a statistically significant improvement in left ventricle ejection fraction, the interest of Dr. Giannetti and Dr. Cecere and the MUHC Foundation is pivotal, as it enables Hemostemix to raise additional non-dilutive clinical trial funding. Investors can also choose to support this exciting innovation through a tax-deductible donation to the MUHC Foundation,\" stated Thomas Smeenk, CEO. \"Innovation is key to advancing medicine. The MUHC Foundation is proud to help bring this ground-breaking clinical trial to the MUHC. Our partnership with Hemostemix will not only benefit patients at the MUHC living with cardiomyopathy, but create new knowledge that will benefit people with the disease across Canada and around the world,\" says Julie Quenneville, President, MUHC Foundation. Dr. Giannetti received her medical degree from McGill University. After training in cardiology at McGill, she went on to pursue a Fellowship in Heart Failure and Cardiac Transplantation at Stanford University in California. She returned to McGill to ...